L-glutamine and prescription use
What 2 graded rows on l-glutamine agree on for prescription use, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the L-glutamine page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the L-glutamine page, with its PubMed record.
Your question
L-glutamine and prescription use
2 rows · 283 peopleThey agree: both rows found an improvement.
- BGrade B× 1
- DGrade D× 1
- Rows
- 2
- Trials
- 2
- People
- 283
What the rows share
From the rowsThe best-graded row, grade B, is a randomized trial of 230 people (2018) and found an improvement.
The rows run from 53 to 230 people, published from 2018 to 2026: 2 single studies.
The rows
2 improved- BGrade BPain crises in sickle cell anaemia · Improved
RCT · n 230 · 2018 · Children and adults (5–58 years) with sickle cell anaemia
0.3 g/kg twice daily (prescription dosing) · 48 weeks
Median pain crises were lower than with placebo, with or without hydroxyurea; nausea, chest pain, fatigue and musculoskeletal pain were more common.
Row on the L-glutamine page · PubMed 30021096 (opens PubMed)
- DGrade DPain crises in sickle cell anaemia, added to hydroxyurea · Improved
RCT · n 53 · 2026 · Children and adolescents with HbSS or HbS/β0-thalassaemia continuing hydroxyurea (about 20 mg/kg/day)
0.3 g/kg twice daily, up to 30 g a day (from full text) · 6 months
Fewer vaso-occlusive crises (1.00 vs 1.65; p=0.003) and acute chest syndrome episodes (0.19 vs 0.77; p=0.006) than hydroxyurea plus placebo, and 40% fewer hospitalisations (p=0.04). No serious adverse events occurred.
Row on the L-glutamine page · PubMed 41664386 (opens PubMed)